nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—MAPT—amyotrophic lateral sclerosis	0.506	1	CbGaD
Lansoprazole—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.152	0.428	CbGbCtD
Lansoprazole—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.141	0.395	CbGbCtD
Lansoprazole—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.0628	0.177	CbGbCtD
Lansoprazole—Pleural disorder—Riluzole—amyotrophic lateral sclerosis	0.00686	0.057	CcSEcCtD
Lansoprazole—Oesophageal stenosis—Riluzole—amyotrophic lateral sclerosis	0.00418	0.0348	CcSEcCtD
Lansoprazole—Biliary colic—Riluzole—amyotrophic lateral sclerosis	0.00265	0.022	CcSEcCtD
Lansoprazole—Proctitis—Riluzole—amyotrophic lateral sclerosis	0.00265	0.022	CcSEcCtD
Lansoprazole—Stridor—Riluzole—amyotrophic lateral sclerosis	0.00198	0.0165	CcSEcCtD
Lansoprazole—Hemiplegia—Riluzole—amyotrophic lateral sclerosis	0.00181	0.0151	CcSEcCtD
Lansoprazole—Rectal tenesmus—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0144	CcSEcCtD
Lansoprazole—Dementia—Riluzole—amyotrophic lateral sclerosis	0.00158	0.0131	CcSEcCtD
Lansoprazole—Paraesthesia oral—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0115	CcSEcCtD
Lansoprazole—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.00138	0.0115	CcSEcCtD
Lansoprazole—Renal pain—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0102	CcSEcCtD
Lansoprazole—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00983	CcSEcCtD
Lansoprazole—Urine abnormality—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00971	CcSEcCtD
Lansoprazole—Hostility—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00971	CcSEcCtD
Lansoprazole—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00948	CcSEcCtD
Lansoprazole—Gingival bleeding—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00948	CcSEcCtD
Lansoprazole—Urine analysis abnormal—Riluzole—amyotrophic lateral sclerosis	0.0011	0.00914	CcSEcCtD
Lansoprazole—Platelet count decreased—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00904	CcSEcCtD
Lansoprazole—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00894	CcSEcCtD
Lansoprazole—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00884	CcSEcCtD
Lansoprazole—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00106	0.00884	CcSEcCtD
Lansoprazole—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00874	CcSEcCtD
Lansoprazole—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00855	CcSEcCtD
Lansoprazole—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00846	CcSEcCtD
Lansoprazole—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.000997	0.00829	CcSEcCtD
Lansoprazole—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.000987	0.00821	CcSEcCtD
Lansoprazole—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00094	0.00781	CcSEcCtD
Lansoprazole—Haemoglobin decreased—Riluzole—amyotrophic lateral sclerosis	0.00094	0.00781	CcSEcCtD
Lansoprazole—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.000931	0.00774	CcSEcCtD
Lansoprazole—Haematemesis—Riluzole—amyotrophic lateral sclerosis	0.000931	0.00774	CcSEcCtD
Lansoprazole—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.000922	0.00767	CcSEcCtD
Lansoprazole—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.000914	0.0076	CcSEcCtD
Lansoprazole—Apathy—Riluzole—amyotrophic lateral sclerosis	0.000905	0.00753	CcSEcCtD
Lansoprazole—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.000897	0.00746	CcSEcCtD
Lansoprazole—Haemoptysis—Riluzole—amyotrophic lateral sclerosis	0.000874	0.00726	CcSEcCtD
Lansoprazole—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.000859	0.00714	CcSEcCtD
Lansoprazole—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.000837	0.00696	CcSEcCtD
Lansoprazole—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.000804	0.00669	CcSEcCtD
Lansoprazole—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.000798	0.00664	CcSEcCtD
Lansoprazole—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.000798	0.00664	CcSEcCtD
Lansoprazole—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.000786	0.00654	CcSEcCtD
Lansoprazole—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00078	0.00649	CcSEcCtD
Lansoprazole—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.000741	0.00616	CcSEcCtD
Lansoprazole—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.000731	0.00608	CcSEcCtD
Lansoprazole—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.000721	0.00599	CcSEcCtD
Lansoprazole—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.000716	0.00595	CcSEcCtD
Lansoprazole—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.000711	0.00591	CcSEcCtD
Lansoprazole—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.000706	0.00587	CcSEcCtD
Lansoprazole—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.000702	0.00583	CcSEcCtD
Lansoprazole—Gout—Riluzole—amyotrophic lateral sclerosis	0.000693	0.00576	CcSEcCtD
Lansoprazole—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.000684	0.00568	CcSEcCtD
Lansoprazole—Cataract—Riluzole—amyotrophic lateral sclerosis	0.000679	0.00565	CcSEcCtD
Lansoprazole—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.000655	0.00544	CcSEcCtD
Lansoprazole—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.000647	0.00538	CcSEcCtD
Lansoprazole—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.000647	0.00538	CcSEcCtD
Lansoprazole—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.000643	0.00535	CcSEcCtD
Lansoprazole—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.000639	0.00531	CcSEcCtD
Lansoprazole—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.000639	0.00531	CcSEcCtD
Lansoprazole—Melaena—Riluzole—amyotrophic lateral sclerosis	0.000632	0.00525	CcSEcCtD
Lansoprazole—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.000617	0.00513	CcSEcCtD
Lansoprazole—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.000607	0.00505	CcSEcCtD
Lansoprazole—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.000607	0.00505	CcSEcCtD
Lansoprazole—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.000594	0.00494	CcSEcCtD
Lansoprazole—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.000567	0.00471	CcSEcCtD
Lansoprazole—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00055	0.00457	CcSEcCtD
Lansoprazole—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00055	0.00457	CcSEcCtD
Lansoprazole—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00449	CcSEcCtD
Lansoprazole—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00054	0.00449	CcSEcCtD
Lansoprazole—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.000535	0.00445	CcSEcCtD
Lansoprazole—Deafness—Riluzole—amyotrophic lateral sclerosis	0.000525	0.00436	CcSEcCtD
Lansoprazole—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000525	0.00436	CcSEcCtD
Lansoprazole—Injury—Riluzole—amyotrophic lateral sclerosis	0.000511	0.00425	CcSEcCtD
Lansoprazole—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.000506	0.00421	CcSEcCtD
Lansoprazole—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.0005	0.00415	CcSEcCtD
Lansoprazole—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.0005	0.00415	CcSEcCtD
Lansoprazole—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.000497	0.00414	CcSEcCtD
Lansoprazole—Thirst—Riluzole—amyotrophic lateral sclerosis	0.000493	0.0041	CcSEcCtD
Lansoprazole—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000487	0.00405	CcSEcCtD
Lansoprazole—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.000485	0.00403	CcSEcCtD
Lansoprazole—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000483	0.00402	CcSEcCtD
Lansoprazole—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.000471	0.00392	CcSEcCtD
Lansoprazole—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000469	0.0039	CcSEcCtD
Lansoprazole—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.000469	0.0039	CcSEcCtD
Lansoprazole—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.000469	0.0039	CcSEcCtD
Lansoprazole—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.000466	0.00387	CcSEcCtD
Lansoprazole—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.000462	0.00384	CcSEcCtD
Lansoprazole—Migraine—Riluzole—amyotrophic lateral sclerosis	0.000462	0.00384	CcSEcCtD
Lansoprazole—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.000453	0.00377	CcSEcCtD
Lansoprazole—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.000446	0.00371	CcSEcCtD
Lansoprazole—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.000445	0.0037	CcSEcCtD
Lansoprazole—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.000437	0.00363	CcSEcCtD
Lansoprazole—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.000433	0.0036	CcSEcCtD
Lansoprazole—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00355	CcSEcCtD
Lansoprazole—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000424	0.00353	CcSEcCtD
Lansoprazole—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000423	0.00351	CcSEcCtD
Lansoprazole—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.000415	0.00345	CcSEcCtD
Lansoprazole—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000414	0.00344	CcSEcCtD
Lansoprazole—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.000414	0.00344	CcSEcCtD
Lansoprazole—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.000408	0.0034	CcSEcCtD
Lansoprazole—Influenza—Riluzole—amyotrophic lateral sclerosis	0.000406	0.00337	CcSEcCtD
Lansoprazole—Asthma—Riluzole—amyotrophic lateral sclerosis	0.000406	0.00337	CcSEcCtD
Lansoprazole—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000406	0.00337	CcSEcCtD
Lansoprazole—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.000398	0.00331	CcSEcCtD
Lansoprazole—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.000395	0.00329	CcSEcCtD
Lansoprazole—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00039	0.00324	CcSEcCtD
Lansoprazole—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000389	0.00323	CcSEcCtD
Lansoprazole—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000385	0.0032	CcSEcCtD
Lansoprazole—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000379	0.00315	CcSEcCtD
Lansoprazole—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.000379	0.00315	CcSEcCtD
Lansoprazole—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.000375	0.00312	CcSEcCtD
Lansoprazole—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000374	0.00311	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00037	0.00308	CcSEcCtD
Lansoprazole—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000369	0.00307	CcSEcCtD
Lansoprazole—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000364	0.00303	CcSEcCtD
Lansoprazole—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000362	0.00301	CcSEcCtD
Lansoprazole—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000362	0.00301	CcSEcCtD
Lansoprazole—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.000357	0.00297	CcSEcCtD
Lansoprazole—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00295	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.000355	0.00295	CcSEcCtD
Lansoprazole—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000353	0.00293	CcSEcCtD
Lansoprazole—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.000353	0.00293	CcSEcCtD
Lansoprazole—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000352	0.00292	CcSEcCtD
Lansoprazole—Sweating—Riluzole—amyotrophic lateral sclerosis	0.000347	0.00288	CcSEcCtD
Lansoprazole—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.000345	0.00287	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000342	0.00284	CcSEcCtD
Lansoprazole—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00284	CcSEcCtD
Lansoprazole—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00282	CcSEcCtD
Lansoprazole—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000338	0.00281	CcSEcCtD
Lansoprazole—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.000331	0.00275	CcSEcCtD
Lansoprazole—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.000326	0.00271	CcSEcCtD
Lansoprazole—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.000325	0.0027	CcSEcCtD
Lansoprazole—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00269	CcSEcCtD
Lansoprazole—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.000323	0.00269	CcSEcCtD
Lansoprazole—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000322	0.00268	CcSEcCtD
Lansoprazole—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000321	0.00267	CcSEcCtD
Lansoprazole—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00032	0.00266	CcSEcCtD
Lansoprazole—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000319	0.00265	CcSEcCtD
Lansoprazole—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000318	0.00265	CcSEcCtD
Lansoprazole—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000307	0.00255	CcSEcCtD
Lansoprazole—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000303	0.00252	CcSEcCtD
Lansoprazole—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000301	0.00251	CcSEcCtD
Lansoprazole—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000295	0.00245	CcSEcCtD
Lansoprazole—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000293	0.00244	CcSEcCtD
Lansoprazole—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000293	0.00243	CcSEcCtD
Lansoprazole—Chills—Riluzole—amyotrophic lateral sclerosis	0.000291	0.00242	CcSEcCtD
Lansoprazole—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00029	0.00241	CcSEcCtD
Lansoprazole—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000287	0.00239	CcSEcCtD
Lansoprazole—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000285	0.00237	CcSEcCtD
Lansoprazole—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000283	0.00235	CcSEcCtD
Lansoprazole—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000279	0.00232	CcSEcCtD
Lansoprazole—Tension—Riluzole—amyotrophic lateral sclerosis	0.000277	0.00231	CcSEcCtD
Lansoprazole—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.000277	0.0023	CcSEcCtD
Lansoprazole—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.000275	0.00228	CcSEcCtD
Lansoprazole—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000273	0.00227	CcSEcCtD
Lansoprazole—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000272	0.00226	CcSEcCtD
Lansoprazole—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000265	0.0022	CcSEcCtD
Lansoprazole—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000262	0.00218	CcSEcCtD
Lansoprazole—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000261	0.00217	CcSEcCtD
Lansoprazole—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00026	0.00216	CcSEcCtD
Lansoprazole—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.000258	0.00215	CcSEcCtD
Lansoprazole—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000255	0.00212	CcSEcCtD
Lansoprazole—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000254	0.00211	CcSEcCtD
Lansoprazole—Syncope—Riluzole—amyotrophic lateral sclerosis	0.000254	0.00211	CcSEcCtD
Lansoprazole—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000253	0.0021	CcSEcCtD
Lansoprazole—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00025	0.00208	CcSEcCtD
Lansoprazole—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000248	0.00207	CcSEcCtD
Lansoprazole—Cough—Riluzole—amyotrophic lateral sclerosis	0.000247	0.00205	CcSEcCtD
Lansoprazole—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000245	0.00204	CcSEcCtD
Lansoprazole—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000244	0.00203	CcSEcCtD
Lansoprazole—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000241	0.002	CcSEcCtD
Lansoprazole—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000241	0.002	CcSEcCtD
Lansoprazole—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000241	0.002	CcSEcCtD
Lansoprazole—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00024	0.00199	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000239	0.00199	CcSEcCtD
Lansoprazole—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000238	0.00198	CcSEcCtD
Lansoprazole—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000235	0.00196	CcSEcCtD
Lansoprazole—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000233	0.00193	CcSEcCtD
Lansoprazole—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000231	0.00192	CcSEcCtD
Lansoprazole—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000231	0.00192	CcSEcCtD
Lansoprazole—Infection—Riluzole—amyotrophic lateral sclerosis	0.000229	0.00191	CcSEcCtD
Lansoprazole—Shock—Riluzole—amyotrophic lateral sclerosis	0.000227	0.00189	CcSEcCtD
Lansoprazole—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000226	0.00188	CcSEcCtD
Lansoprazole—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000226	0.00188	CcSEcCtD
Lansoprazole—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000225	0.00187	CcSEcCtD
Lansoprazole—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000224	0.00186	CcSEcCtD
Lansoprazole—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000223	0.00185	CcSEcCtD
Lansoprazole—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00022	0.00183	CcSEcCtD
Lansoprazole—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000216	0.00179	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00021	0.00175	CcSEcCtD
Lansoprazole—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000209	0.00174	CcSEcCtD
Lansoprazole—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000207	0.00172	CcSEcCtD
Lansoprazole—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000206	0.00171	CcSEcCtD
Lansoprazole—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000205	0.00171	CcSEcCtD
Lansoprazole—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000203	0.00169	CcSEcCtD
Lansoprazole—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000201	0.00167	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000199	0.00166	CcSEcCtD
Lansoprazole—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000199	0.00165	CcSEcCtD
Lansoprazole—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000197	0.00164	CcSEcCtD
Lansoprazole—Pain—Riluzole—amyotrophic lateral sclerosis	0.000197	0.00164	CcSEcCtD
Lansoprazole—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00019	0.00158	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000189	0.00157	CcSEcCtD
Lansoprazole—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000183	0.00152	CcSEcCtD
Lansoprazole—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000182	0.00152	CcSEcCtD
Lansoprazole—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000182	0.00152	CcSEcCtD
Lansoprazole—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00017	0.00141	CcSEcCtD
Lansoprazole—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000166	0.00138	CcSEcCtD
Lansoprazole—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000163	0.00136	CcSEcCtD
Lansoprazole—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000158	0.00131	CcSEcCtD
Lansoprazole—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000153	0.00127	CcSEcCtD
Lansoprazole—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000147	0.00122	CcSEcCtD
Lansoprazole—Rash—Riluzole—amyotrophic lateral sclerosis	0.000145	0.00121	CcSEcCtD
Lansoprazole—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000145	0.00121	CcSEcCtD
Lansoprazole—Headache—Riluzole—amyotrophic lateral sclerosis	0.000145	0.0012	CcSEcCtD
Lansoprazole—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000137	0.00114	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—TP53—amyotrophic lateral sclerosis	3.48e-05	0.00188	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	3.44e-05	0.00186	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.43e-05	0.00185	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	3.4e-05	0.00184	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	3.36e-05	0.00182	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—DAO—amyotrophic lateral sclerosis	3.33e-05	0.0018	CbGpPWpGaD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	3.32e-05	0.0018	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	3.28e-05	0.00178	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	3.27e-05	0.00177	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	3.27e-05	0.00177	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—FIG4—amyotrophic lateral sclerosis	3.22e-05	0.00174	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	3.2e-05	0.00173	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	3.1e-05	0.00167	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	3.07e-05	0.00166	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	3.07e-05	0.00166	CbGpPWpGaD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	3.05e-05	0.00165	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	3.01e-05	0.00163	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.97e-05	0.00161	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.97e-05	0.00161	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.95e-05	0.00159	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—DAO—amyotrophic lateral sclerosis	2.91e-05	0.00158	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	2.89e-05	0.00156	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.86e-05	0.00155	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	2.84e-05	0.00153	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	2.82e-05	0.00152	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	2.8e-05	0.00152	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	2.8e-05	0.00151	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.77e-05	0.0015	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	2.75e-05	0.00149	CbGpPWpGaD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	2.72e-05	0.00147	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.72e-05	0.00147	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.7e-05	0.00146	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.7e-05	0.00146	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.69e-05	0.00145	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	2.63e-05	0.00142	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	2.62e-05	0.00142	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.61e-05	0.00141	CbGpPWpGaD
Lansoprazole—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	2.6e-05	0.00141	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	2.59e-05	0.0014	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PLB1—amyotrophic lateral sclerosis	2.53e-05	0.00137	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.53e-05	0.00137	CbGpPWpGaD
Lansoprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	2.48e-05	0.00134	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.47e-05	0.00134	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.45e-05	0.00132	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.4e-05	0.0013	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.4e-05	0.0013	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	2.4e-05	0.0013	CbGpPWpGaD
Lansoprazole—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.39e-05	0.00129	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.38e-05	0.00128	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	2.36e-05	0.00128	CbGpPWpGaD
Lansoprazole—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.35e-05	0.00127	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GSR—amyotrophic lateral sclerosis	2.33e-05	0.00126	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.3e-05	0.00124	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	2.27e-05	0.00122	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	2.25e-05	0.00122	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.23e-05	0.0012	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PLB1—amyotrophic lateral sclerosis	2.21e-05	0.00119	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.19e-05	0.00118	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.16e-05	0.00117	CbGpPWpGaD
Lansoprazole—CYP2C8—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.16e-05	0.00117	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—DAO—amyotrophic lateral sclerosis	2.15e-05	0.00116	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.14e-05	0.00115	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.12e-05	0.00115	CbGpPWpGaD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	2.12e-05	0.00115	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.09e-05	0.00113	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	2.06e-05	0.00112	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GSR—amyotrophic lateral sclerosis	2.04e-05	0.0011	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	2e-05	0.00108	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	1.95e-05	0.00106	CbGpPWpGaD
Lansoprazole—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.95e-05	0.00106	CbGpPWpGaD
Lansoprazole—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.93e-05	0.00104	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CHAT—amyotrophic lateral sclerosis	1.91e-05	0.00104	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.84e-05	0.000996	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	1.83e-05	0.000989	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	1.83e-05	0.000989	CbGpPWpGaD
Lansoprazole—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.8e-05	0.000972	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	1.78e-05	0.000965	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.78e-05	0.000963	CbGpPWpGaD
Lansoprazole—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.77e-05	0.000958	CbGpPWpGaD
Lansoprazole—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.76e-05	0.00095	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.75e-05	0.000944	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	1.71e-05	0.000924	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.71e-05	0.000922	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	1.69e-05	0.000913	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.68e-05	0.000908	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TPK1—amyotrophic lateral sclerosis	1.68e-05	0.000907	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—VAPB—amyotrophic lateral sclerosis	1.68e-05	0.000907	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	1.67e-05	0.000905	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—CHAT—amyotrophic lateral sclerosis	1.67e-05	0.000905	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	1.67e-05	0.000905	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.63e-05	0.00088	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	1.61e-05	0.000871	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.56e-05	0.000846	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.56e-05	0.000841	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—VAPA—amyotrophic lateral sclerosis	1.53e-05	0.000829	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	1.52e-05	0.000824	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.52e-05	0.000823	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GSR—amyotrophic lateral sclerosis	1.5e-05	0.000812	CbGpPWpGaD
Lansoprazole—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.5e-05	0.000812	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	1.5e-05	0.000809	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	1.5e-05	0.000809	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.48e-05	0.000801	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.46e-05	0.000791	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	1.46e-05	0.00079	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	1.46e-05	0.00079	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	1.45e-05	0.000784	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.44e-05	0.000776	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.43e-05	0.000771	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.4e-05	0.000755	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	1.38e-05	0.000745	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	1.38e-05	0.000745	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	1.37e-05	0.00074	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.37e-05	0.00074	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	1.37e-05	0.000739	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	1.37e-05	0.000738	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	1.37e-05	0.000738	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—FIG4—amyotrophic lateral sclerosis	1.34e-05	0.000725	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	1.34e-05	0.000723	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	1.32e-05	0.000715	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	1.3e-05	0.0007	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	1.3e-05	0.0007	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.27e-05	0.000688	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.27e-05	0.000688	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.26e-05	0.000681	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	1.25e-05	0.000675	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.24e-05	0.000672	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.23e-05	0.000667	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—DAO—amyotrophic lateral sclerosis	1.21e-05	0.000656	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.2e-05	0.000647	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	1.2e-05	0.000647	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.17e-05	0.000635	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.17e-05	0.000633	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	1.17e-05	0.000632	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	1.17e-05	0.000631	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	1.17e-05	0.000631	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.16e-05	0.000628	CbGpPWpGaD
Lansoprazole—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.16e-05	0.000627	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	1.15e-05	0.000624	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.13e-05	0.000609	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.12e-05	0.000607	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.1e-05	0.000595	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	1.1e-05	0.000592	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	1.09e-05	0.00059	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.09e-05	0.000588	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	1.08e-05	0.000585	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	1.07e-05	0.000577	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.06e-05	0.000571	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.03e-05	0.000556	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	1e-05	0.000542	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	9.96e-06	0.000538	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.92e-06	0.000536	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	9.87e-06	0.000534	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.46e-06	0.000511	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	9.33e-06	0.000504	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	9.25e-06	0.0005	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PLB1—amyotrophic lateral sclerosis	9.19e-06	0.000497	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	9.09e-06	0.000491	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	9e-06	0.000487	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	9e-06	0.000487	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.99e-06	0.000486	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSR—amyotrophic lateral sclerosis	8.48e-06	0.000459	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	8.43e-06	0.000456	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.43e-06	0.000456	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.43e-06	0.000456	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.26e-06	0.000447	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	8.23e-06	0.000445	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	8.2e-06	0.000444	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	8.01e-06	0.000433	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—APOE—amyotrophic lateral sclerosis	7.78e-06	0.000421	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.72e-06	0.000418	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.71e-06	0.000417	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	7.66e-06	0.000414	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.6e-06	0.000411	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	7.57e-06	0.000409	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.55e-06	0.000408	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	7.48e-06	0.000404	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	7.39e-06	0.0004	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	7.2e-06	0.000389	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.16e-06	0.000387	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CHAT—amyotrophic lateral sclerosis	6.97e-06	0.000377	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	6.96e-06	0.000376	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.93e-06	0.000375	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	6.9e-06	0.000373	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.89e-06	0.000373	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—APOE—amyotrophic lateral sclerosis	6.8e-06	0.000368	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.63e-06	0.000358	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	6.51e-06	0.000352	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	6.39e-06	0.000346	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.36e-06	0.000344	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.29e-06	0.00034	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	6.22e-06	0.000336	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.09e-06	0.000329	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	6.07e-06	0.000328	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.03e-06	0.000326	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	5.9e-06	0.000319	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.72e-06	0.000309	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.67e-06	0.000307	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	5.67e-06	0.000306	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.54e-06	0.0003	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.41e-06	0.000292	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.37e-06	0.00029	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.33e-06	0.000288	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.17e-06	0.00028	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—APOE—amyotrophic lateral sclerosis	5.01e-06	0.000271	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	4.93e-06	0.000267	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.84e-06	0.000262	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.75e-06	0.000257	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.66e-06	0.000252	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	4.56e-06	0.000247	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	4.55e-06	0.000246	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.42e-06	0.000239	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.35e-06	0.000235	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.08e-06	0.000221	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.89e-06	0.00021	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.75e-06	0.000203	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.74e-06	0.000202	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	3.74e-06	0.000202	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.54e-06	0.000192	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.44e-06	0.000186	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.44e-06	0.000186	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.34e-06	0.000181	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.26e-06	0.000176	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.13e-06	0.000169	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	3.09e-06	0.000167	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.07e-06	0.000166	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.07e-06	0.000166	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.05e-06	0.000165	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.03e-06	0.000164	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3e-06	0.000162	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—APOE—amyotrophic lateral sclerosis	2.83e-06	0.000153	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.82e-06	0.000153	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.8e-06	0.000151	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.6e-06	0.000141	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	2.53e-06	0.000137	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	2.47e-06	0.000133	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.39e-06	0.000129	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.32e-06	0.000126	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	2.3e-06	0.000125	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.12e-06	0.000114	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.01e-06	0.000109	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	1.97e-06	0.000106	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.94e-06	0.000105	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.85e-06	9.98e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.73e-06	9.36e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.69e-06	9.13e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.59e-06	8.61e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.58e-06	8.53e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.52e-06	8.21e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.35e-06	7.29e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.04e-06	5.63e-05	CbGpPWpGaD
